SENP6 and lymphoma: In summary, starting from an in vivo cancer gene discovery screen, we have identified SENP6 deletions and associated unrestricted SUMOylation as a functional and clinically important driver of lymphomagenesis, and we have demonstrated SENP6’s downstream effectors as potential effective lymphoma treatment targets.